Axonics, Inc. (AXNX) |
|
48.54 -1.11 (-2.24%)
|
05-26 16:00 |
|
Open: |
48.44 |
Pre. Close: |
49.65 |
|
High:
|
50.34 |
Low:
|
48.38 |
|
Volume:
|
532,148 |
Market Cap:
|
2,446(M) |
|
|
|
Technical analysis |
as of: 2023-05-26 4:21:35 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 65.89  One year: 71.7 |
| Support: |
Support1: 48.38 Support2: 40.25 |
| Resistance: |
Resistance1: 56.42 Resistance2: 61.38 |
| Pivot: |
52.79 |
| Moving Average: |
MA(5): 50.26 MA(20): 53.14
MA(100): 57.17 MA(250): 62.2 |
| MACD: |
MACD(12,26): -1.8 Signal(9): -1.3 |
| Stochastic oscillator: |
%K(14,3): 7.9 %D(3): 12.3 |
| RSI: |
RSI(14): 34 |
| 52-week: |
High: 79.91 Low: 46.56 |
| Average Vol(K): |
3-Month: 628 (K) 10-Days: 541 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AXNX ] has closed above bottom band by 4.6%. Bollinger Bands are 10.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
50.4 - 50.81 |
50.81 - 51.08 |
|
Low:
|
47.54 - 47.99 |
47.99 - 48.29 |
|
Close:
|
47.96 - 48.65 |
48.65 - 49.11 |
|
Company Description |
|
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. |
Headline News |
Thu, 25 May 2023
'We're Going Up': Billionaire Steve Cohen Loads Up on These 2 ... - Nasdaq
Mon, 22 May 2023
Sectoral Asset Management Inc. Sells 26650 Shares of Axonics, Inc ... - MarketBeat
Tue, 16 May 2023
Russell Investments Group Ltd. Sells 20301 Shares of Axonics, Inc ... - MarketBeat
Mon, 15 May 2023
What Makes Axonics (AXNX) Unique? - Yahoo Finance
Fri, 12 May 2023
Axonics: Attractive Strong Growth Profile (NASDAQ:AXNX) - Seeking Alpha
Mon, 08 May 2023
When Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable? - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
50 (M) |
| Shares Float |
50 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
103.2 (%) |
|
Shares Short
|
4,120 (K) |
|
Shares Short P.Month
|
4,050 (K) |
Stock Financials |
|
EPS
|
-0.94 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
11.51 |
|
Profit Margin (%)
|
-15.7 |
|
Operating Margin (%)
|
-10.6 |
|
Return on Assets (ttm)
|
-3.3 |
|
Return on Equity (ttm)
|
-8.9 |
|
Qtrly Rev. Growth
|
45.9 |
|
Gross Profit (p.s.)
|
3.92 |
|
Sales Per Share
|
5.87 |
|
EBITDA (p.s.)
|
-0.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
12 (M) |
|
Levered Free Cash Flow
|
47 (M) |
Stock Valuations |
|
PE Ratio
|
-51.64 |
|
PEG Ratio
|
-2 |
|
Price to Book value
|
4.21 |
|
Price to Sales
|
8.26 |
|
Price to Cash Flow
|
211.17 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
